PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 22, 20260 citationsOpen Access

CL5D Hybrid Model for Protein–Ligand Interaction Dynamics

View Full Paper
MCMrinmoy Chakraborty

Key Points

  • The central aim is to describe protein-ligand binding dynamics more accurately using the CL5D model.
  • Developed a hybrid model integrating multiple scientific concepts for protein-ligand interactions.
  • Applied the model to analyze 33 BACE1 inhibitors with known IC50 values.
  • Classified interactions into four distinct phases based on binding characteristics.
  • 32 out of 33 compounds classified in Phase I, indicating good binding interactions.
  • One ligand identified as having unique characteristics in Phase II with notable kinetics.
  • The model predicts specific binding behaviors that could aid in the design of more effective drugs.

Abstract

The accurate description of protein–ligand binding dynamics remains a challenge for staticstructural methods such as X-ray crystallography and cryo-EM. Here we introduce theCL5D hybrid model, a deterministic, agent-based framework that integrates entropy (At), fractal geometry (Ab), harmonic progression (Ex), and permutation entropy (T) to computea single Cn score. The Cn score classifies interactions into four phases: Phase I (Excellent/ Good / Moderate / Bad / Very bad), Phase II (Evolution and Decay), Phase III (singularity), and Phase IV (cycle reset). We apply CL5D to 33 BACE1 inhibitors withreported IC50 values (0. 0002–0. 149nM at 2 ◦C). While 32 compounds fall into Phase I, one ligand (Monomer 209917, IC50 = 0. 0002 nM) uniquely enters Phase II (Decay) withCn = 7. 04 × 10^−5. This compound is identified as a Super Dynamic Candidate, predictedto exhibit ultra-fast on/off kinetics, a shallow energy well, and near-perfect pocketentry—potentially involving quantum tunnelling. The CL5D model offers a new lens fordynamic drug design, distinguishing classical reversible binders from rare, super-efficaciousmolecules.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mrinmoy Chakraborty (2026) studied this question.

synapsesocial.com/papers/69e866416e0dea528ddeaa76https://doi.org/10.5281/zenodo.19662109
Ask AI
Helpful
Bookmark
Share
View Full Paper